Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis: Complete Statistical AnalysisIndependent statistical analysis of Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04731129).
- Minimally Invasive Surgery (MIS) Database for the Purpose of Research: Complete Statistical AnalysisIndependent statistical analysis of Minimally Invasive Surgery (MIS) Database for the Purpose of Research: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00535990).
- MIRACLEA detailed statistical analysis of the randomized phase 2 MIRACLE trial evaluating everolimus with goserelin and letrozole in patients with metastatic breast cancer, including trial design, progression-free survival, planned statistical methods, interpretation,…
- MIRASIndependent statistical analysis of MIRAS (NCT07690332), a real-world study of mirvetuximab soravtansine in ovarian cancer and related cancers with folate receptor α expression.
- MITO-7Independent statistical analysis of MITO-7, a randomized phase 3 trial comparing weekly versus every 3 week chemotherapy in patients with ovarian cancer.
- MITO-8Independent statistical analysis of the randomized phase 3 MITO-8 trial in ovarian cancer, including its crossover design, overall survival endpoint, planned analysis, and statistical interpretation.
- MK-3475 Immunotherapy in Endometrial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of MK-3475 Immunotherapy in Endometrial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02630823).
- MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- MMVAR – Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: Complete Statistical AnalysisIndependent statistical analysis of MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01355679).
- Molecular-Guided Therapy for Childhood Cancer: Complete Statistical AnalysisIndependent statistical analysis of Molecular-Guided Therapy for Childhood Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02162732).
- Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG): Complete Statistical AnalysisIndependent statistical analysis of Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01182350).
- MONALEESA-2Complete statistical analysis of MONALEESA-2, the randomized phase 3 trial of ribociclib plus letrozole versus placebo plus letrozole in postmenopausal women with advanced or metastatic breast cancer.
- MONALEESA-7Independent statistical analysis of MONALEESA-7, a randomized phase 3 trial of ribociclib plus endocrine therapy and goserelin versus placebo plus endocrine therapy and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced…
- MONARCH 1Independent statistical analysis of MONARCH 1 (NCT02102490), a phase 2 single-group study of abemaciclib in participants with previously treated metastatic breast cancer, including trial design, endpoints, planned statistical analysis, interpretation, and limitations.
- MONARCH 1Independent statistical analysis of A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- MONARCH 3Independent statistical analysis of the phase 3 MONARCH 3 trial of abemaciclib plus a nonsteroidal aromatase inhibitor in postmenopausal women with breast cancer, including progression-free survival, response, health-status outcomes, methodology, safety, and…
- MONARCH plusIndependent statistical analysis of A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02763566).
- Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00549328).
- Morpheus LungIndependent statistical analysis of A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer): primary endpoint results, effect estimate with confidence interval,…
- MOST EMPOWERIndependent statistical analysis of MOST EMPOWER: Optimizing An Emotion Regulation Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04317417).
- MOUNTAINEERIndependent statistical analysis of the phase 2 MOUNTAINEER trial of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal adenocarcinoma, including trial design, cORR methodology, safety, and statistical interpretation.
- MOUNTAINEER-03Independent statistical analysis of the phase 3 MOUNTAINEER-03 trial evaluating tucatinib with trastuzumab and mFOLFOX6 versus standard-of-care treatment in first-line HER2+ metastatic colorectal cancer.
- Move For Your Health for Older Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Move For Your Health for Older Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05582889).
- MOVESIndependent statistical analysis of MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03820024).
- MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- MRC CR07An educational statistical analysis of MRC CR07 (NCT00003422), a randomized phase 3 trial comparing radiation therapy before surgery with chemotherapy plus radiation after surgery in surgically removable rectal cancer.
- MRI Guided SBRT for Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of MRI Guided SBRT for Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03778112).
- MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- MSC2015103B in Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of MSC2015103B in Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01453387).
- MUCINIndependent statistical analysis of Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.: Complete Statistical AnalysisIndependent statistical analysis of Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint…
- Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy: primary endpoint results, effect estimate with confidence interval,…
- Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only…
- Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery: Complete Statistical AnalysisIndependent statistical analysis of Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- My-CRAIndependent statistical analysis of Oral Liquid 13-cis-retinoic Acid (13-CRA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03291080).
- MYCureIndependent statistical analysis of Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- MyoSure Hysteroscopic Tissue Removal System Registry Study: Complete Statistical AnalysisIndependent statistical analysis of MyoSure Hysteroscopic Tissue Removal System Registry Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01369758).
- Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA: Complete Statistical AnalysisIndependent statistical analysis of Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01893801).
- Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence…
- Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with…